BioTuesdays

Category - Markets

Eloxx Pharma
Markets

HCW slashes Eloxx Pharma PT to $3 from $10

H.C. Wainwright slashed its price target for Eloxx Pharmaceuticals (NASDAQ:ELOX) to $3 from $10 and retained its “neutral” rating, saying the strength of the company’s ELX-02 program in cystic fibrosis is yet to be...

March 6, 2020
Osmotica Pharmaceuticals
Markets

SVB Leerink starts Osmotica Pharma at OP; PT $10

SVB Leerink launched coverage of Osmotica Pharmaceuticals (NASDAQ:OSMT) with an “outperform rating” and $10 price target. The stock closed at $5.47 on March 5. Analyst Ami Fadia writes that her rating is based on the...

March 6, 2020
Precision Biosciences
Markets

Stifel starts Precision Biosciences at buy; PT $21

Stifel initiated coverage of Precision Biosciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $8.11 on March 4. “Our positive thesis is predicated on optimism that Precision’s allogeneic...

March 5, 2020
Co-Diagnostics
Markets

Maxim cuts Co-Diagnostics to hold; removes PT

Maxim Group downgraded Co-Diagnostics (NASDAQ:CODX) to “hold” from “buy” and removed its price target, reflecting a meteoric rise in the company’s stock price in 2020. The stock closed at $17.81 on March 2. Analyst...

March 3, 2020
Avita Medical
Markets

BTIG starts Avita Medical at buy; PT $10

BTIG launched coverage of Avita Medical (NASDAQ:RCEL) with a “buy” rating and $10 price target. The stock closed at $8.32 on March 2. Avita’s RECELL system produces a suspension of spray-on-skin cells using a small...

March 3, 2020
Extendicare
Markets

Echelon ups Extendicare to buy; holds PT at $9

Echelon Wealth Partners upgraded Extendicare (TSX:EXE) to “buy” from “hold” but kept its price target at $9 after the company reported fourth quarter results. The stock closed at $7.85 (Canadian) on March 2. Analyst...

March 3, 2020
IMV-Logo
Markets

BTIG cuts IMV PT to $5 from $8

BTIG lowered its price target for IMV (NASDAQ, TSX:IMV) to $5 from $8, citing uncertainty about data from the company’s ongoing Phase 2 study of DPX-Survivac in patients with advanced recurrent ovarian cancer. The stock...

February 28, 2020